Abstract
Emerging and resurgent arboviral diseases are a major public health problem for developing countries, particularly in Latin America and Africa, for the severity of their symptoms and lethality. Vaccines are recognized as the most powerful preventive, low-risk and cost-effective interventions. For this reason, vaccines against these arboviral diseases could have an extensive impact on global health. Nevertheless, many gaps persist in innovation and technological development of these vaccines and it is necessary and urgent to accelerate new funding mechanisms and incentives, such as “patent pools”, with active participation of manufacturers in developing countries, to assure their cost-effectiveness, efficacy and minimize their potential adverse effects. In this global scenario, intellectual property, especially patents documents, have emerged as a crucial issue for vaccine development. The global patent landscape for vaccines against these four arboviral diseases has undergone drastic changes in the past 5 years, with breakthroughs resulting from advances in molecular biology and genetic engineering: DNA vaccines, recombinant vaccines based on antigens expressed in vectors (viral, bacterial, yeast) and vaccines obtained through reverse vaccinology, with the selection of potential candidates at the genetic level rather than the protein level. Our main aim is to transcend the conventional debate on vaccine development and ethical, regulatory and policy issues, already explored in many scientific publications in the past three decades and determine which of these issues should be considered new and specific to this new perspective. Finally, an adequate use of patent documents, as indicated here, can be a valuable source of information, supporting technological prospect tools in more effective knowledge governance strategies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Derwent Manual Code is a classification attributed in the Derwent Innovation® database to all the patent documents indexed in it. This classification also has a hierarchical structure, such as the International Classification of Patents, although in less detail. The Manual Codes divide the technological knowledge contained in the patent documents into 21 sections.
References
Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney M-C, Medits I, Sharma A et al (2016) Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536(7614):48–53
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL et al (2013) The global distribution and burden of dengue. Nature 496:504–507
Brown D, Hernandez R (2003) Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype. US Patent 6,589,533, 08 Jul 2003
Crowe JE, Koff WC (2015) Deciphering the human immunome. Expert Rev Vaccines 14:1421–1425
Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, Duangchinda T et al (2016) Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat Immunol 17(9):1102–1108
Foss N (2007) The emerging knowledge governance approach: challenges and characteristics. Organization 14(1):29–52
Foss N, Husted K, Michailova S (2010) Governing knowledge sharing in organiza-tions: levels of analysis, governance mechanisms, and research directions. J Manag Stud 47(3):455–482
Garske T, Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, Staples JE et al (2014) Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data. PLoS Med. https://doi.org/10.1371/journal.pmed.1001638
Halstead S (2017) Biologic evidence required for Zika disease enhancement by dengue antibodies. Emerg Infect Dis 23(4):569–573
Isern S, Michael SF (2017) Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes. US Patent 2017202945, 20 Jul 2017
Koff WC, Gust ID, Plotkin SA (2014) Toward a human vaccines project. Nat Immunol 15:589–592
Lagunas-Rangel FA, Viveros-Sandoval ME, Reyes Sandoval A (2017) Current trends in Zika vaccine development. J Virus Erad 3(3):124–127
Ministry of Health Brazil (2017) Monitoring dengue, chikungunya fever and Zika virus fever up to epidemiological week 51, 2016. Secretary of health surveillance. Epidemiol Bull. 2017 48(2):10
Paul LM, Carlin ER, Jenkins MM, Tan AL, Barcellona CM, Nicholson CO et al (2016) Dengue virus antibodies enhance Zika virus infection. Clin Transl Immunol 5(12):e117
Possas C (2016) Zika: what we do and do not know based on the experiences of Brazil. Epidemiol Health 38:e2016023. https://doi.org/10.4178/epih.e2016023
Possas C, Antunes AMS, Mendes FML, Schumacher SDOR, Martins RM, Homma A (2015) Access to new technologies in multipatented vaccines: challenges for Brazil. Nat Biotechnol 33(6):599–603
Possas C, Brasil P, Marzochi M, Tanuri A, Martins RM, Marques Ernesto TA et al (2017) Zika puzzle in Brazil: peculiar conditions of viral introduction and dissemination – a review. Mem Inst Oswaldo Cruz 112(55):319–327
Priyamvada L, Quicke KM, Hudson WH, Onlamoon N, Sewatanon J, Edupuganti S et al (2016) Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci USA 113(28):7852–7857
Rivino L, Lim MQ (2016) CD4+ and CD8+ T-celll immunity to dengue – lessons for the study of Zika virus. Immunology 150:146–154
Sette A, Rappuoli R (2010) Reverse vaccinology: developing vaccines in the era of genomics. Immunity 33:530–541
Singh HB, Jha A, Keswani C (eds) (2016) Intellectual property issues in biotechnology. CABI, Oxfordshire, p 304
WHO (2017a) Yellow fever fact sheet. World Health Organization. Geneva. Updated May 2016. http://www.who.int/mediacentre/factsheets/fs100/en/
WHO (2017b) Dengue and severe dengue fact sheet. World Health Organization, Geneva. Updated April 2017. http://www.who.int/mediacentre/factsheets/fs117/en/
Wilder-Smith A, Gubler DJ, Weaver SC, Monath TP, Heymann DL, Scott TW (2017) Epidemic arboviral diseases: priorities for research and public health. Lancet Infect Dis 17(3):e101–e106
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Possas, C., Antunes, A.M.S., Mendes, F.M.L., Martins, R.M., Homma, A. (2019). Emerging and Resurgent Arboviral Diseases: Global Vaccine Patent Landscape and the Case for Immunome. In: Singh, H., Keswani, C., Singh, S. (eds) Intellectual Property Issues in Microbiology. Springer, Singapore. https://doi.org/10.1007/978-981-13-7466-1_18
Download citation
DOI: https://doi.org/10.1007/978-981-13-7466-1_18
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-7465-4
Online ISBN: 978-981-13-7466-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)